Semaglutide (Ozempic, Wegovy, Rybelsus)

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It's a modified version of the human GLP-1 hormone, engineered with substitutions and a fatty acid chain that protect it from rapid degradation and allow once-weekly dosing.^[1]

It is available as three FDA-approved products: Ozempic (weekly injection for type 2 diabetes), Wegovy (weekly injection for chronic weight management), and Rybelsus (daily oral tablet for type 2 diabetes). The compound itself is the same molecule across products — what differs is dose, formulation, and approved indication.

Semaglutide emerged from a long line of GLP-1 mimetics that began with the discovery of exendin-4 in Gila monster venom (Eng, 1992) and was extended through Novo Nordisk's research into long-acting GLP-1 analogs. The molecule was first published in 2012 (Lau et al., J Med Chem) as a successor to liraglutide — engineered for once-weekly rather than daily dosing through a longer fatty-acid linker that promotes albumin binding.

It was first FDA-approved as Ozempic for type 2 diabetes in December 2017, followed by Rybelsus (the first oral GLP-1, 2019), and Wegovy for chronic weight management in 2021. The 2023 SELECT cardiovascular outcomes trial extended its indication into cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease.

Semaglutide mimics endogenous GLP-1, a hormone released by intestinal L-cells after eating. It binds and activates the GLP-1 receptor, which is expressed in pancreatic beta cells, the gut, and — importantly for weight loss — multiple brain regions including the hypothalamus and brainstem.^[1]

The main physiologic effects are:

• Glucose-dependent insulin release from pancreatic beta cells (lowering glucose without typical hypoglycemia risk).
• Suppression of glucagon when glucose is elevated.
• Slowed gastric emptying, producing earlier and longer satiety after meals.
• Central appetite suppression via action on hypothalamic and brainstem circuits regulating food intake.

The slowed gastric emptying attenuates over time with continued use, but the central appetite effects persist, which is why sustained weight loss is possible.

Semaglutide's roughly seven-day half-life is the result of a deliberate set of structural modifications: an Aib substitution at position 8 to resist DPP-4 cleavage, a single amino acid swap at position 34, and a C18 fatty diacid attached via a short linker at lysine-26. The fatty diacid binds reversibly to albumin, which both extends circulation time and slows renal clearance.

Subcutaneous bioavailability is approximately 89%. Steady-state plasma concentrations are reached after roughly 4–5 weeks of weekly dosing. Oral semaglutide (Rybelsus) achieves clinically relevant exposure through co-formulation with the absorption enhancer SNAC, despite the inherent challenge of orally absorbing a peptide.

The peer-reviewed literature on Semaglutide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

In the clinical trials and FDA-approved labeling, semaglutide 2.4 mg (Wegovy) is administered as a once-weekly subcutaneous injection, with a 16-week titration schedule starting at 0.25 mg to manage gastrointestinal side effects. Ozempic uses a similar titration up to 1.0 mg or 2.0 mg weekly. Rybelsus is an oral formulation taken daily on an empty stomach.

This site does not provide dosing instructions. Use under medical supervision.

Semaglutide stands as one of the most consequential pharmacology stories of the past decade. The combination of its weight-loss magnitude, glycemic control, and now-confirmed cardiovascular benefit gives it an evidence base broader and deeper than almost any other peptide molecule.

For people working with their clinicians on type 2 diabetes or obesity, the central question is no longer whether semaglutide works but how to use it well. That includes thoughtful titration to manage GI side effects, protein intake and resistance training to preserve lean mass, and a long-view conversation about chronic-disease pharmacotherapy: like statins or antihypertensives, semaglutide tends to require ongoing use to maintain its benefits.

Practitioners and patients exploring this space should also follow the latest readouts from the SELECT, FLOW, and STEP-HFpEF programs — semaglutide's story is still being written, particularly in cardiorenal disease.